Shares of Foghorn Therapeutics Inc. fell more than 3% on Monday afternoon, after hitting intraday lows last seen over 10 ...

Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug ...

The partnership with Eli Lilly represents a significant opportunity for Foghorn Therapeutics. The $300 million upfront payment provides substantial financial resources to advance the company's ...

Foghorn Therapeutics Inc. (NASDAQ ... notable aspects of Foghorn's business strategy is its partnership with Eli Lilly and Company (NYSE:LLY). This collaboration, which includes Lilly's oncology ...

Foghorn Therapeutics (FHTX) has made the decision to discontinue the independent development of FHD-286 in combination with decitabine in ...

Foghorn Therapeutics on Monday said it is ending independent development of its FHD-286 drug candidate following disappointing results from an early-stage study.

Jefferies lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $14 from $18 and keeps a Buy rating on ... The firm views this decision as “unsurprising” given the high efficacy benchmark ...

Jefferies lowered the firm’s price target on Foghorn Therapeutics (FHTX ... set by standard-of-care venetoclax and believes Eli Lilly (LLY) allied SMARCA2 inhibitor FHD-909 “remains the ...

The partnership with Eli Lilly represents a significant opportunity for Foghorn Therapeutics. The $300 million upfront payment provides substantial financial resources to advance the company's ...

Foghorn Therapeutics has a market capitalization of $390 million, with the stock priced at $6.26 per share. The company holds a cash position of $285 million, providing a runway for continued research ...

H.C. Wainwright lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $13 from $20 and keeps a Buy rating on the ...

Foghorn Therapeutics shares are trading lower by ... Selective EP300 and ARID1B, along with its Lilly collaboration, which includes the development of FHD-909. Partnerships and Investigator ...